Axsome Therapeutics DEF 14A: Executive Compensation Details
Ticker: AXSM · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1579428
| Field | Detail |
|---|---|
| Company | Axsome Therapeutics, INC. (AXSM) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, stock-awards, proxy-statement
Related Tickers: AXSM
TL;DR
AXSM DEF 14A out: exec comp & stock awards for 2020-2024 detailed. Check fair values.
AI Summary
Axsome Therapeutics, Inc. filed a DEF 14A on April 25, 2025, detailing executive compensation and stock awards. The filing includes information on the fair value of equity awards granted and vested for the fiscal years ending December 31, 2020, through December 31, 2024, for both executive and non-executive members. Specific dollar amounts for these awards are detailed within the filing.
Why It Matters
This filing provides transparency into how Axsome Therapeutics compensates its top executives, which can influence investor perception of management alignment with shareholder interests.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not present new material risks to the company.
Key Numbers
- 2020-2024 — Fiscal Years Covered (Reporting period for executive compensation and equity awards.)
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Filer of the DEF 14A
- 20250425 (date) — Filing date of the DEF 14A
- December 31, 2020 (date) — Fiscal year end for which compensation data is reported
- December 31, 2024 (date) — Fiscal year end for which compensation data is reported
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing is used to solicit proxy votes from shareholders for an upcoming annual meeting, and it also provides detailed information on executive compensation, director nominations, and other corporate governance matters.
What specific types of equity awards are detailed in this filing for Axsome Therapeutics?
The filing details the change in fair value of outstanding and unvested equity awards, as well as the vesting dates for equity awards granted and vested, for both executive and non-executive members.
For which fiscal years does Axsome Therapeutics provide compensation data in this filing?
Axsome Therapeutics provides compensation data for the fiscal years ending December 31, 2020, through December 31, 2024.
What is the Central Index Key (CIK) for Axsome Therapeutics?
The Central Index Key (CIK) for Axsome Therapeutics, Inc. is 0001579428.
Where is Axsome Therapeutics, Inc. headquartered?
Axsome Therapeutics, Inc. is headquartered at One World Trade Center, 29th Floor, New York, NY 10007.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Axsome Therapeutics, Inc. (AXSM).